{"id":1023,"date":"2026-05-11T05:44:00","date_gmt":"2026-05-11T12:44:00","guid":{"rendered":"https:\/\/www.getasecondopinion.ai\/blog\/?p=1023"},"modified":"2026-05-18T17:46:15","modified_gmt":"2026-05-19T00:46:15","slug":"fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/","title":{"rendered":"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.getasecondopinion.ai\/medication\/tazverik\">Tazverik<\/a>, a prescription cancer drug used to treat certain rare cancers, has recently come under closer scrutiny by the U.S. Food and Drug Administration. In a safety alert, the FDA warned health care providers and patients about an increased risk of developing new blood cancers in people treated with Tazverik. This announcement has raised understandable concerns among patients and families who rely on the medication, as well as those considering it as part of their treatment plan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Is Tazverik and Who Uses It?<\/strong><\/h3>\n\n\n\n<p>Tazverik, also known by its generic name tazemetostat, is a targeted cancer therapy. It works by blocking a specific enzyme involved in cancer cell growth. The FDA originally approved Tazverik to treat two rare conditions:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epithelioid sarcoma<\/strong>, a slow-growing soft tissue cancer that often affects young adults.<\/li>\n\n\n\n<li><strong>Follicular lymphoma<\/strong>, a type of non-Hodgkin lymphoma, in patients whose cancer has returned or did not respond to other treatments.<\/li>\n<\/ul>\n\n\n\n<p>Because these cancers are uncommon and sometimes difficult to treat, Tazverik offered hope as a new option, especially for patients who had already tried other therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Prompted the FDA Safety Alert?<\/strong><\/h3>\n\n\n\n<p>The FDA issued its alert after reviewing long-term safety data from clinical trials and follow-up studies involving patients who took Tazverik. Over time, some patients developed <strong>new blood cancers<\/strong>, including forms of leukemia and myelodysplastic syndrome, which affects how blood cells are made in the bone marrow.<\/p>\n\n\n\n<p>These secondary cancers did not appear immediately. In many cases, they developed months or even years after treatment began. While the number of affected patients was relatively small, the seriousness of these conditions led the FDA to take action and inform the public.<\/p>\n\n\n\n<p>The FDA emphasized that this risk appears to be linked to how Tazverik works at a cellular level. By altering certain genetic processes, the drug may unintentionally increase the chance of abnormal blood cell growth in some individuals.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Understanding the Risk<\/strong><\/h3>\n\n\n\n<p>It is important to put the FDA warning into context. Not everyone who takes Tazverik will develop a new blood cancer. The risk is considered <strong>rare<\/strong>, but it is also <strong>serious<\/strong>.<\/p>\n\n\n\n<p>Think of it like this: Tazverik is designed to interfere with cancer cells, but in doing so, it may also affect healthy cells involved in blood production. Over time, this disruption can increase the chance that those cells become cancerous themselves.<\/p>\n\n\n\n<p>The FDA has not recommended stopping Tazverik for all patients. Instead, it urges careful monitoring and informed decision-making.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Symptoms Should Patients Watch For?<\/strong><\/h3>\n\n\n\n<p>Patients taking Tazverik should be aware of symptoms that could signal a blood-related problem. These symptoms can be vague and easy to overlook, which is why regular checkups are important.<\/p>\n\n\n\n<p>Possible warning signs include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ongoing fatigue or weakness<\/li>\n\n\n\n<li>Frequent infections<\/li>\n\n\n\n<li>Easy bruising or bleeding<\/li>\n\n\n\n<li>Shortness of breath<\/li>\n\n\n\n<li>Pale skin<\/li>\n\n\n\n<li>Unexplained fevers<\/li>\n<\/ul>\n\n\n\n<p>These symptoms do not automatically mean cancer, but they should be reported to a health care provider promptly.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Doctors Are Being Advised to Respond<\/strong><\/h3>\n\n\n\n<p>The FDA has advised health care providers to take several steps when prescribing or managing patients on Tazverik:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Discuss the potential risk of new blood cancers before starting treatment.<\/li>\n\n\n\n<li>Monitor blood counts regularly during treatment and after it ends.<\/li>\n\n\n\n<li>Watch for early signs of bone marrow problems.<\/li>\n\n\n\n<li>Weigh the benefits of Tazverik against its risks, especially for long-term use.<\/li>\n<\/ul>\n\n\n\n<p>Doctors are also encouraged to report any new cases of blood cancers linked to Tazverik to the FDA\u2019s MedWatch system. This helps regulators track patterns and update safety guidance as needed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why the FDA Did Not Pull Tazverik from the Market<\/strong><\/h3>\n\n\n\n<p>Some patients may wonder why the FDA did not remove Tazverik entirely. The answer lies in the balance between risk and benefit.<\/p>\n\n\n\n<p>For certain patients with limited treatment options, Tazverik can slow cancer progression or shrink tumors. In life-threatening situations, even a small chance of benefit can outweigh long-term risks, especially when alternatives are few.<\/p>\n\n\n\n<p>The FDA determined that, with proper warnings and monitoring, Tazverik\u2019s benefits still justify its availability for specific patients.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What This Means for Current Patients<\/strong><\/h3>\n\n\n\n<p>If you or a loved one is currently taking Tazverik, the FDA does not recommend stopping the medication without consulting a doctor. Abruptly stopping cancer treatment can be dangerous.<\/p>\n\n\n\n<p>Instead, patients should:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Schedule a conversation with their oncologist.<\/li>\n\n\n\n<li>Ask about personal risk factors.<\/li>\n\n\n\n<li>Review blood test results regularly.<\/li>\n\n\n\n<li>Discuss whether continued treatment makes sense based on current health and treatment goals.<\/li>\n<\/ul>\n\n\n\n<p>Every patient\u2019s situation is different, and decisions should be made on an individual basis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What About Patients Considering Tazverik?<\/strong><\/h3>\n\n\n\n<p>For patients who have not yet started Tazverik, the FDA alert adds another factor to consider. Doctors may discuss alternative treatments, shorter treatment durations, or closer monitoring plans.<\/p>\n\n\n\n<p>Informed consent is key. Patients should feel comfortable asking questions such as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>How likely is this risk for someone like me?<\/li>\n\n\n\n<li>Are there other treatment options?<\/li>\n\n\n\n<li>How will we monitor for problems?<\/li>\n\n\n\n<li>What symptoms should I report right away?<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Ongoing Research and Monitoring<\/strong><\/h3>\n\n\n\n<p>The FDA continues to monitor Tazverik\u2019s safety profile. Drug safety does not end at approval. As more patients use a medication over time, rare side effects can emerge that were not obvious in early trials.<\/p>\n\n\n\n<p>Researchers are also studying why some patients develop secondary blood cancers while others do not. Factors such as genetics, prior cancer treatments, and overall health may play a role.<\/p>\n\n\n\n<p>Future updates from the FDA could lead to changes in prescribing guidelines, additional warnings, or new recommendations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The Bigger Picture of Cancer Drug Safety<\/strong><\/h3>\n\n\n\n<p>Tazverik is not the only cancer drug linked to secondary cancers. Some chemotherapy and radiation treatments have long been known to increase the risk of later blood cancers. What makes this situation notable is that Tazverik is a targeted therapy, which many people assume is safer than older treatments.<\/p>\n\n\n\n<p>This reminder underscores an important reality: all cancer treatments involve trade-offs. Advances in medicine continue to improve outcomes, but no therapy is completely risk-free.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Key Takeaways for Patients and Families<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The FDA has warned of a rare but serious risk of new blood cancers in patients treated with Tazverik.<\/li>\n\n\n\n<li>The risk appears months or years after treatment in some cases.<\/li>\n\n\n\n<li>Patients should not stop treatment without medical advice.<\/li>\n\n\n\n<li>Regular blood monitoring and symptom awareness are essential.<\/li>\n\n\n\n<li>Open communication with health care providers is critical.<\/li>\n<\/ul>\n\n\n\n<p>Staying informed empowers patients to make decisions that align with their values and health goals.<\/p>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-custom-off-white-background-color has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/cta-background-01.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-153751c2 wp-block-group-is-layout-constrained\" style=\"padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-b6fe6b9c1e90c3ca0e3d22a4a0e21d9e\">Better Treatment, Lower Cost &#8211; No Catch.<\/h3>\n\n\n\n<p>Find safer, more effective medications with fewer side effects &#8211; often for less money. It\u2019s fast, free, and personalized. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Sources (3)<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik\">https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik<\/a>\u00a0<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/tazemetostathydrobromide\">https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/tazemetostathydrobromide<\/a>\u00a0<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/druginfo\/meds\/a620032.html\">https:\/\/medlineplus.gov\/druginfo\/meds\/a620032.html<\/a>\u00a0<\/li>\n<\/ol>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tazverik, a prescription cancer drug used to treat certain rare cancers, has recently come under closer scrutiny by the U.S. Food and Drug Administration. In a safety alert, the FDA warned health care providers and patients about an increased risk of developing new blood cancers in people treated with Tazverik. This announcement has raised understandable [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":1024,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[822,828,748,825,829,824,830,826,827,823],"class_list":["post-1023","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fda-updates","tag-blood-cancer-risk","tag-cancer-treatment-risks","tag-fda-drug-safety","tag-fda-safety-alert","tag-medical-news-update","tag-oncology-news","tag-patient-safety-alert","tag-targeted-therapy-side-effects","tag-tazemetostat-warning","tag-tazverik-cancer-drug"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"FDA warns Tazverik may raise risk of new blood cancers. Learn what this means for patients and doctors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"FDA warns Tazverik may raise risk of new blood cancers. Learn what this means for patients and doctors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-11T12:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T00:46:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/05\/Tazverik.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik\",\"datePublished\":\"2026-05-11T12:44:00+00:00\",\"dateModified\":\"2026-05-19T00:46:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/\"},\"wordCount\":1092,\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Tazverik.jpg\",\"keywords\":[\"blood cancer risk\",\"cancer treatment risks\",\"FDA drug safety\",\"FDA safety alert\",\"medical news update\",\"oncology news\",\"patient safety alert\",\"targeted therapy side effects\",\"tazemetostat warning\",\"Tazverik cancer drug\"],\"articleSection\":[\"FDA Updates\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/\",\"name\":\"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Tazverik.jpg\",\"datePublished\":\"2026-05-11T12:44:00+00:00\",\"dateModified\":\"2026-05-19T00:46:15+00:00\",\"description\":\"FDA warns Tazverik may raise risk of new blood cancers. Learn what this means for patients and doctors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Tazverik.jpg\",\"contentUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Tazverik.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Professional medical editorial header showing the headline \u201cFDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik\u201d over a blurred, modern laboratory background in cool blue and gray tones with clean negative space and molecular motifs.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Policy Alerts\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/policy-alerts\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA Updates\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/policy-alerts\\\/fda-updates\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"contentUrl\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/getasecondopinion\",\"https:\\\/\\\/www.instagram.com\\\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik - Get a Second Opinion","description":"FDA warns Tazverik may raise risk of new blood cancers. Learn what this means for patients and doctors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/","og_locale":"en_US","og_type":"article","og_title":"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik - Get a Second Opinion","og_description":"FDA warns Tazverik may raise risk of new blood cancers. Learn what this means for patients and doctors.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2026-05-11T12:44:00+00:00","article_modified_time":"2026-05-19T00:46:15+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/05\/Tazverik.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik","datePublished":"2026-05-11T12:44:00+00:00","dateModified":"2026-05-19T00:46:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/"},"wordCount":1092,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/05\/Tazverik.jpg","keywords":["blood cancer risk","cancer treatment risks","FDA drug safety","FDA safety alert","medical news update","oncology news","patient safety alert","targeted therapy side effects","tazemetostat warning","Tazverik cancer drug"],"articleSection":["FDA Updates"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/","name":"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/05\/Tazverik.jpg","datePublished":"2026-05-11T12:44:00+00:00","dateModified":"2026-05-19T00:46:15+00:00","description":"FDA warns Tazverik may raise risk of new blood cancers. Learn what this means for patients and doctors.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/05\/Tazverik.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/05\/Tazverik.jpg","width":1536,"height":1024,"caption":"Professional medical editorial header showing the headline \u201cFDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik\u201d over a blurred, modern laboratory background in cool blue and gray tones with clean negative space and molecular motifs."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-warns-of-increased-risk-of-new-blood-cancers-linked-to-tazverik\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"Policy Alerts","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/policy-alerts\/"},{"@type":"ListItem","position":3,"name":"FDA Updates","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/policy-alerts\/fda-updates\/"},{"@type":"ListItem","position":4,"name":"FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/1023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=1023"}],"version-history":[{"count":1,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/1023\/revisions"}],"predecessor-version":[{"id":1025,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/1023\/revisions\/1025"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/1024"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=1023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=1023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=1023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}